{"prompt": "['MEIRAGTx', '5.4.2', 'Protocol defined clinical schedule', '35', '5.4.2.1', 'Baseline Assessments', '35', '5.4.2.2', 'ATIMP administration Procedures', '37', '5.4.2.2.1 Pre-operative Procedures', '37', '5.4.2.2.2', 'Technique for intraocular administration of ATIMP', '38', '5.4.2.3', 'Subsequent Assessments', '38', '5.4.2.4', 'Laboratory Procedures', '40', '5.4.3', 'Dispensing', '41', '5.4.3.1', 'Receipt and Storage of the Advanced Therapy Investigational Medicinal Product', '41', '5.4.4', 'Dosages', '41', '5.4.4.1 Dosages and dosage modifications', '41', '5.4.5', 'Accountability', '42', '5.4.6', 'Compliance and Adherence', '42', '5.4.7', 'Concomitant Care', '42', '5.4.8', 'Overdose of Trial Medication', '42', '5.4.9', 'Protocol Discontinuation', '42', '5.4.9.1', 'Participant Withdrawal', '42', '5.4.9.2', 'Trial Stopping Rules', '43', '5.5', 'Outcomes', '43', '5.5.1', 'Primary Outcomes', '43', '5.5.2', 'Secondary Outcomes', '44', '5.6', 'Trial Assessments', '45', '5.6.1', 'Early Stopping of Follow-up', '47', '5.6.2', 'Loss to Follow-up', '47', '5.6.3', 'Trial Closure', '47', '5.6.4', 'Long Term Follow-Up After the End of the Trial', '47', '5.7', 'Sample Size', '47', '5.8', 'Recruitment and Retention', '47', '5.8.1', 'Recruitment', '47', '5.8.2', 'Retention', '47', '5.9', 'Assignment of Intervention', '48', '5.9.1', 'Allocation', '48', 'CNGA3 MGT012 Protocol version 5.0 09Jul2020 Page 4 of 68']['MEIRAGTx', '5.10', 'Data Collection, Management and Analysis', '48', '5.10.1', 'Data collection, management and entry', '48', '5.10.2', 'Non-Adherence and Non-Retention', '49', '5.10.3', 'Statistical Methods', '49', '5.10.3.1', 'Statistical Analysis Plan', '49', '5.10.3.2', 'Statistical Methods - Primary Outcome Analysis', '49', '5.10.3.3', 'Statistical Methods - Secondary Outcome Analysis', '49', '5.10.3.4', 'Statistical Methods - Health Economics Analysis', '50', '5.11', 'Data Monitoring', '50', '5.11.1', 'Safety Data Monitoring Committee', '50', '5.11.2', 'Interim Analyses', '50', '5.11.3', 'Data Monitoring for Harm', '50', '5.11.3.1', 'Safety reporting', '50', '5.11.3.2', 'Other Notifiable Adverse Events', '52', '5.11.3.3', 'Procedures to follow in the event of female participants becoming pregnant. 52', '5.11.3.4', 'Procedures to follow in the event of the partners of male participants becoming', 'pregnant', '52', '5.11.3.5', 'Investigator responsibilities relating to safety reporting', '53', '5.11.3.5.1', 'Seriousness assessment', '53', '5.11.3.5.2', 'Severity or grading of Adverse Events', '53', '5.11.3.5.3', 'Causality', '54', '5.11.3.5.4', 'Expectedness', '54', '5.11.3.6', 'Notifications', '56', '5.11.3.6.1 Notifications by the Investigator to Pharmacovigilance', '56', '5.11.3.6.2', 'Reporting Urgent Safety Measures', '56', '5.11.3.6.3', 'PV Service Provider responsibilities', '57', '5.11.3.6.4', 'Reporting SUSARs in International Trials', '57', '5.11.3.6.5', 'Annual Progress Reports', '57', '5.11.4', 'Quality Assurance and Control', '57', '5.11.4.1', 'Risk Assessment', '57', '5.11.4.2', 'Clinical Monitoring', '57', '5.11.4.3', 'Direct access to participant records', '57', '5.11.4.4', 'Trial Oversight', '57', 'CNGA3 MGT012 Protocol version 5.0 09Jul2020 Page 5 of 68']\n\n###\n\n", "completion": "END"}